The Effect of Amantadine on Post-COVD-19 Fatigue

• Status: Not yet recruiting
• Trial end date: 2023-01-10
• Target enrollment: 0
• Participant gender: All

Summary

This study aimed to investigate amantadine's safety and its effect on reducing post-COVID-19 fatigue.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shahid Beheshti University of Medical Sciences
• Treatments: Amantadine

Criteria

Inclusion Criteria:

• clinical diagnosis of COVID-19

• clinical evidence of fatigue despite the passage of 30 to 60 days from the onset --of the symptoms of COVID-19

• willingness and informed consent to participate in the study

Exclusion Criteria:

• the recurrence of COVID-19 in the form of re-infection

• history of psychiatric diseases

• psychotic disorders (in the form of hallucinations and delusions)

• anxiety disorders and major depression

• substance abuse in the last four months

• taking antidepressants during the last six weeks

• corticosteroids consumption during the last six weeks

• taking psychostimulant drugs

• an unstable medical condition

• cognitive disorders and confusion

• withdrawal from participating in the study

• history of rheumatological disease

• getting cancer and malignancy

• advanced chronic diseases (heart, liver, kidney, etc.)

• edema of organs

• hypertension (untreated)

• hypogonadism (untreated)

• hypothyroidism (untreated)

• anemia (untreated)

• pregnancy and breastfeeding

• nausea and vomiting when starting to take Amantadine

• convulsions

• dyspnea

• post-COVID-19 encephalopathy